SCHEMBL1742865

SCHEMBL1742865

FC(F)(F)c1ccc(-c2ccc(N3CCNCC3)nc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.57
ADRB1 P08588 1/20 0.55
KCNH2 Q12809 4/20 0.52
DGAT1 O75907 4/20 0.52
SOAT1 P35610 2/20 0.52
MGLL Q99685 1/20 0.50
CACNA1C Q13936 1/20 0.50
ASIC3 Q9UHC3 1/20 0.50
PRMT5 O14744 1/20 0.47
PIM1 P11309 1/20 0.47
PIM3 Q86V86 1/20 0.47
PIM2 Q9P1W9 1/20 0.47
METAP2 P50579 1/20 0.46
ADRB2 P07550 2/20 0.46
KDM4E B2RXH2 1/20 0.45
ABL1 P00519 1/20 0.45
LMNA P02545 1/20 0.45
NCF1 P14598 1/20 0.45
IKBKE Q14164 1/20 0.45
TBK1 Q9UHD2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17035908 0.88 ADRB1 (0.60) ADRB1ADRB2KDM4EABL1LMNA
SCHEMBL30101389 0.88 ADRB1 (0.60) ADRB1ADRB2KDM4EABL1LMNA
SCHEMBL231823 0.88 ADRB1 (0.60) ADRB1ADRB2KDM4EABL1LMNA
Hydrochloric Acid SCHEMBL9530917 0.86 ADRB1 (0.59) ADRB1ADRB2KDM4EABL1LMNA
Hydrochloric Acid SCHEMBL9394896 0.86 ADRB1 (0.59) ADRB1ADRB2KDM4EABL1LMNA
SCHEMBL5623553 0.85 KDM4E (0.59) KCNH2DGAT1SOAT1MGLLKDM4E
SCHEMBL6785729 0.84 ADRB1 (0.49) ADRB1KCNH2PIM1PIM3PIM2
SCHEMBL12911528 0.83 GPR119 (0.58) GPR119KCNH2CACNA1CASIC3IKBKE
SCHEMBL2155294 0.82 ADRB1 (0.55) ADRB1KDM4EABL1LMNA
SCHEMBL30567235 0.82 ADRB1 (0.55) ADRB1KDM4EABL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
EP-2233470-A1 Histamine H3 receptor antagonists High Point Pharmaceuticals, LLC (US) 2010-09-29 EP disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 EP disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 GPR119 198/4885ADRB1 336/4885KCNH2 2830/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 GPR119 198/4885ADRB1 336/4885KCNH2 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.